371 related articles for article (PubMed ID: 27704399)
1. Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI).
Capdevila J; Galofré JC; Grande E; Zafón Llopis C; Ramón Y Cajal Asensio T; Navarro González E; Jiménez-Fonseca P; Santamaría Sandi J; Gómez Sáez JM; Riesco Eizaguirre G
Clin Transl Oncol; 2017 Mar; 19(3):279-287. PubMed ID: 27704399
[TBL] [Abstract][Full Text] [Related]
2. Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancer.
Riesco-Eizaguirre G; Galofré JC; Grande E; Zafón Llopis C; Ramón y Cajal Asensio T; Navarro González E; Jiménez-Fonseca P; Santamaría Sandi J; Gómez Sáez JM; Capdevila J
Endocrinol Nutr; 2016 Apr; 63(4):e17-24. PubMed ID: 26601805
[TBL] [Abstract][Full Text] [Related]
3. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.
Capdevila J; Newbold K; Licitra L; Popovtzer A; Moreso F; Zamorano J; Kreissl M; Aller J; Grande E
Cancer Treat Rev; 2018 Sep; 69():164-176. PubMed ID: 30032061
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
5. Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.
Gosain R; Alexander JS; Gill A; Perez C
Curr Oncol Rep; 2018 Sep; 20(10):82. PubMed ID: 30206719
[TBL] [Abstract][Full Text] [Related]
6. Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer.
Sacks W; Braunstein GD
Endocr Pract; 2014 Mar; 20(3):263-75. PubMed ID: 24126232
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine refractory differentiated thyroid cancer.
Jin Y; Van Nostrand D; Cheng L; Liu M; Chen L
Crit Rev Oncol Hematol; 2018 May; 125():111-120. PubMed ID: 29650270
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy in Thyroid Cancer: State of the Art.
Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
Locati LD; Piovesan A; Durante C; Bregni M; Castagna MG; Zovato S; Giusti M; Ibrahim T; Puxeddu E; Fedele G; Pellegriti G; Rinaldi G; Giuffrida D; Verderame F; Bertolini F; Bergamini C; Nervo A; Grani G; Rizzati S; Morelli S; Puliafito I; Elisei R
Eur J Cancer; 2019 Sep; 118():35-40. PubMed ID: 31299580
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
[TBL] [Abstract][Full Text] [Related]
13. Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.
Zhang L; Li Z; Zhang M; Zou H; Bai Y; Liu Y; Lv J; Lv L; Liu P; Deng Z; Liu C
Med Oncol; 2023 Jul; 40(9):258. PubMed ID: 37524925
[TBL] [Abstract][Full Text] [Related]
14. Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation.
Schmidt A; Iglesias L; Klain M; Pitoia F; Schlumberger MJ
Arch Endocrinol Metab; 2017; 61(1):81-89. PubMed ID: 28225999
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology.
Pacini F; Brianzoni E; Durante C; Elisei R; Ferdeghini M; Fugazzola L; Mariotti S; Pellegriti G
J Endocrinol Invest; 2016 Mar; 39(3):341-7. PubMed ID: 26264386
[TBL] [Abstract][Full Text] [Related]
16. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
Gruber JJ; Colevas AD
Oncologist; 2015 Feb; 20(2):113-26. PubMed ID: 25616432
[TBL] [Abstract][Full Text] [Related]
17. Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension.
Kaae AC; Kreissl MC; Krüger M; Infanger M; Grimm D; Wehland M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830100
[TBL] [Abstract][Full Text] [Related]
18. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.
Blumhardt R; Wolin EA; Phillips WT; Salman UA; Walker RC; Stack BC; Metter D
Endocr Relat Cancer; 2014; 21(6):R473-84. PubMed ID: 25277792
[TBL] [Abstract][Full Text] [Related]
19. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.
Narayanan S; Colevas AD
Curr Treat Options Oncol; 2016 Jun; 17(6):30. PubMed ID: 27139457
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
Hegazi M; Azadi A; Jain D; Redman R; Perez CA
Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]